US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CALIDI BIOTHERAPEUTICS INC

0.2845

-0.0105-3.56%

Post-market: 0.2821-0.0024-0.84%19:14 EDT

Volume:927.44K

Turnover:281.92K

Market Cap:2.10M

PE:-0.03

High:0.3011

Open:0.3011

Low:0.2718

Close:0.2950

52wk High:19.20

52wk Low:0.2718

Shares:7.37M

Float Shares:6.36M

Volume Ratio:3.85

T/O Rate:14.57%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-9.0217

EPS(LYR):-35.7001

ROE:--

ROA:-119.65%

PB:0.30

PE(LYR):-0.01

Loading ...

Overview Company News Filings

Calidi Biotherapeutics reports third quarter net loss of $5.2 million

Calidi Biotherapeutics Q3 EPS $(2.21) Misses $(1.68) Estimate

Calidi Biotherapeutics Raises $6.9 Million and Advances RedTail Platform Development

Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights

THOMSON REUTERS

Calidi Biotherapeutics Inc - Qtrly Net Loss per Share, Basic and Diluted, Was $2.21

THOMSON REUTERS

Calidi Biotherapeutics Unveils Promising CLD-401 Data at SITC Annual Meeting

Calidi Biotherapeutics to Present RedTail Platform at SITC Annual Meeting

Calidi Biotherapeutics Selects Matica Bio for CLD-401 Oncolytic Virus Manufacturing

Calidi Biotherapeutics Inc - Following Closing, Nova Cell Is No Longer Subsidiary of Co

THOMSON REUTERS

Calidi Biotherapeutics: on Oct 27, Enters Into Sra & Mpa, With Its Majority Owned Unit, Nova Cell

THOMSON REUTERS

Calidi Biotherapeutics Inc - Sold and Transferred 22.5 Mln Shares of Nova Cell for $6 Mln - SEC Filing

THOMSON REUTERS

Calidi Biotherapeutics Sells Majority Stake in Nova Cell for $6 Million

Calidi Biotherapeutics Unveils New Data on CLD-401 Tumor Therapy at SITC 2025 Annual Meeting

Press Release: Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CLDI/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CLDI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLDI\",,,,,undefined,":{"symbol":"CLDI","market":"US","secType":"STK","nameCN":"CALIDI BIOTHERAPEUTICS INC","latestPrice":0.2845,"timestamp":1774382400000,"preClose":0.295,"halted":0,"volume":927435,"hourTrading":{"tag":"盘后","latestPrice":0.2821,"preClose":0.2845,"latestTime":"19:14 EDT","volume":1920,"amount":538.5815,"timestamp":1774394055890,"change":-0.0024,"changeRate":-0.008436,"amplitude":0.007381},"delay":0,"changeRate":-0.035593220338983086,"floatShares":6364800,"shares":7367000,"eps":-9.021739,"marketStatus":"Closed","change":-0.0105,"latestTime":"03-24 16:00:00 EDT","open":0.3011,"high":0.3011,"low":0.2718,"amount":281918.4823749,"amplitude":0.099322,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-9.021739,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774425600000},"marketStatusCode":5,"adr":0,"exchange":"AMEX","adjPreClose":0.295,"preHourTrading":{"tag":"盘前","latestPrice":0.2951,"preClose":0.295,"latestTime":"09:25 EDT","volume":392333,"amount":124260.21779289999,"timestamp":1774358724481,"change":0.0001,"changeRate":0.000339,"amplitude":0.198983},"postHourTrading":{"tag":"盘后","latestPrice":0.2821,"preClose":0.2845,"latestTime":"19:14 EDT","volume":1920,"amount":538.5815,"timestamp":1774394055890,"change":-0.0024,"changeRate":-0.008436,"amplitude":0.007381},"volumeRatio":3.845492},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLDI\",,,,,undefined,":{"symbol":"CLDI","floatShares":6364800,"roa":"-119.65%","roe":"--","lyrEps":-35.700097,"volumeRatio":3.845492,"shares":7367000,"dividePrice":0,"high":0.3011,"amplitude":0.099322,"preClose":0.295,"low":0.2718,"week52Low":0.2718,"pbRate":"0.30","week52High":19.2,"institutionHeld":0,"latestPrice":0.2845,"eps":-9.021739,"divideRate":0,"volume":927435,"delay":0,"ttmEps":-9.021739,"open":0.3011,"prevYearClose":1.17,"prevWeekClose":0.283,"prevMonthClose":0.7946,"prevQuarterClose":1.17,"fiveDayClose":0.3135,"twentyDayClose":0.7604,"sixtyDayClose":1.29},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CLDI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-05","symbol":"CLDI","defaultRemindTime":1754400600000,"type":"split","dateTimestamp":1754366400000,"forFactor":12,"toFactor":1,"ratio":12},{"market":"US","date":"2024-07-15","symbol":"CLDI","defaultRemindTime":1721050200000,"type":"split","dateTimestamp":1721016000000,"forFactor":10,"toFactor":1,"ratio":10}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CLDI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CLDI\",market:\"US\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":1,"updateTime":1719547200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CLDI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CLDI","date":"2026-03-23","current":-0.031535,"percent":0.993266,"low":-6.02184,"twenty":-1.080993,"median":-0.553956,"eighty":-0.340848,"high":-0.127788,"avg":-0.826942,"sd":0.737436,"marketCap":2984440},"quantilePoints":[{"date":"2023-09-29","current":-3.638343,"twenty":-5.308141,"median":-4.713391,"eighty":-4.212002,"marketCap":116696199},{"date":"2023-10-06","current":-3.412521,"twenty":-4.832341,"median":-4.127586,"eighty":-3.638343,"marketCap":109453210},{"date":"2023-10-13","current":-3.406945,"twenty":-4.642021,"median":-3.525432,"eighty":-3.367913,"marketCap":109274365},{"date":"2023-10-20","current":-3.122569,"twenty":-4.220957,"median":-3.406945,"eighty":-3.283158,"marketCap":100153264},{"date":"2023-10-27","current":-2.788008,"twenty":-3.847474,"median":-3.379065,"eighty":-3.220707,"marketCap":89422557},{"date":"2023-11-03","current":-1.828933,"twenty":-3.642821,"median":-3.289849,"eighty":-2.58281,"marketCap":58661197},{"date":"2023-11-10","current":-2.263862,"twenty":-3.457685,"median":-3.122569,"eighty":-2.272784,"marketCap":72611116},{"date":"2023-11-17","current":-2.442295,"twenty":-3.40806,"median":-2.704368,"eighty":-2.257171,"marketCap":78334160},{"date":"2023-11-24","current":-2.219166,"twenty":-3.390217,"median":-2.436719,"eighty":-2.230406,"marketCap":63785485},{"date":"2023-12-01","current":-2.589027,"twenty":-3.358991,"median":-2.397687,"eighty":-2.219166,"marketCap":74416400},{"date":"2023-12-08","current":-2.860258,"twenty":-3.332227,"median":-2.436719,"eighty":-2.22591,"marketCap":82212403},{"date":"2023-12-15","current":-2.835601,"twenty":-3.283158,"median":-2.620727,"eighty":-2.230406,"marketCap":81503676},{"date":"2023-12-22","current":-2.220879,"twenty":-3.249702,"median":-2.454969,"eighty":-2.220879,"marketCap":63834719},{"date":"2023-12-29","current":-1.739688,"twenty":-3.220707,"median":-2.431143,"eighty":-2.219509,"marketCap":50003863},{"date":"2024-01-05","current":-1.752027,"twenty":-3.147103,"median":-2.407056,"eighty":-2.219166,"marketCap":50358500},{"date":"2024-01-12","current":-1.628644,"twenty":-3.080391,"median":-2.314664,"eighty":-2.158893,"marketCap":46812127},{"date":"2024-01-19","current":-1.492924,"twenty":-2.974346,"median":-2.305467,"eighty":-1.939518,"marketCap":42911116},{"date":"2024-01-26","current":-1.204827,"twenty":-2.880427,"median":-2.269438,"eighty":-1.766833,"marketCap":34630335},{"date":"2024-02-02","current":-0.987855,"twenty":-2.845464,"median":-2.230406,"eighty":-1.702674,"marketCap":28393922},{"date":"2024-02-09","current":-0.730889,"twenty":-2.828204,"median":-2.220879,"eighty":-1.569421,"marketCap":21007953},{"date":"2024-02-16","current":-0.617286,"twenty":-2.802114,"median":-2.220879,"eighty":-1.222224,"marketCap":17742652},{"date":"2024-02-23","current":-1.223953,"twenty":-2.75773,"median":-2.219166,"eighty":-1.201248,"marketCap":35180069},{"date":"2024-03-01","current":-0.737187,"twenty":-2.712314,"median":-2.219166,"eighty":-1.144986,"marketCap":21188964},{"date":"2024-03-08","current":-0.857685,"twenty":-2.707382,"median":-2.174646,"eighty":-1.007118,"marketCap":24652427},{"date":"2024-03-15","current":-0.752972,"twenty":-2.675328,"median":-2.00496,"eighty":-0.959654,"marketCap":21642662},{"date":"2024-03-22","current":-0.731293,"twenty":-2.63341,"median":-1.828933,"eighty":-0.834401,"marketCap":21365466},{"date":"2024-03-28","current":-0.690544,"twenty":-2.624956,"median":-1.776703,"eighty":-0.788933,"marketCap":20174941},{"date":"2024-04-05","current":-0.515506,"twenty":-2.614387,"median":-1.733519,"eighty":-0.77599,"marketCap":15061018},{"date":"2024-04-12","current":-0.778003,"twenty":-2.56475,"median":-1.702674,"eighty":-0.753894,"marketCap":22730126},{"date":"2024-04-19","current":-0.277851,"twenty":-2.462573,"median":-1.585461,"eighty":-0.73922,"marketCap":8117685},{"date":"2024-04-26","current":-0.277851,"twenty":-2.440065,"median":-1.494131,"eighty":-0.729834,"marketCap":8117685},{"date":"2024-05-03","current":-0.33683,"twenty":-2.428199,"median":-1.326872,"eighty":-0.713833,"marketCap":9840816},{"date":"2024-05-10","current":-0.388779,"twenty":-2.412677,"median":-1.223953,"eighty":-0.694949,"marketCap":11358553},{"date":"2024-05-17","current":-0.395215,"twenty":-2.384304,"median":-1.201804,"eighty":-0.67322,"marketCap":11848146},{"date":"2024-05-24","current":-0.389826,"twenty":-2.327552,"median":-1.110439,"eighty":-0.59822,"marketCap":11686581},{"date":"2024-05-31","current":-0.489936,"twenty":-2.314664,"median":-1.049596,"eighty":-0.481812,"marketCap":14687785},{"date":"2024-06-07","current":-0.316825,"twenty":-2.30847,"median":-0.987793,"eighty":-0.405177,"marketCap":9498101},{"date":"2024-06-14","current":-0.471065,"twenty":-2.306068,"median":-0.973968,"eighty":-0.411637,"marketCap":14122049},{"date":"2024-06-21","current":-0.417535,"twenty":-2.287195,"median":-0.942383,"eighty":-0.415168,"marketCap":12517271},{"date":"2024-06-28","current":-0.442801,"twenty":-2.275014,"median":-0.891807,"eighty":-0.416445,"marketCap":13274726},{"date":"2024-07-05","current":-0.415179,"twenty":-2.275014,"median":-0.841776,"eighty":-0.414794,"marketCap":12446661},{"date":"2024-07-12","current":-0.324606,"twenty":-2.266092,"median":-0.802632,"eighty":-0.404243,"marketCap":9731376},{"date":"2024-07-15","current":-0.338952,"twenty":-2.263862,"median":-0.798467,"eighty":-0.400509,"marketCap":10161455},{"date":"2024-08-02","current":-0.357581,"twenty":-2.257171,"median":-0.794302,"eighty":-0.396487,"marketCap":10719918},{"date":"2024-08-09","current":-0.398883,"twenty":-2.230406,"median":-0.779498,"eighty":-0.390904,"marketCap":11958114},{"date":"2024-08-16","current":-0.480755,"twenty":-2.230406,"median":-0.778003,"eighty":-0.392451,"marketCap":11175142},{"date":"2024-08-23","current":-0.500804,"twenty":-2.228501,"median":-0.759804,"eighty":-0.395268,"marketCap":11641180},{"date":"2024-08-30","current":-0.382558,"twenty":-2.220879,"median":-0.750634,"eighty":-0.391354,"marketCap":8892568},{"date":"2024-09-06","current":-0.39647,"twenty":-2.220879,"median":-0.737187,"eighty":-0.391253,"marketCap":9215934},{"date":"2024-09-13","current":-0.403425,"twenty":-2.220879,"median":-0.730361,"eighty":-0.39176,"marketCap":9377617},{"date":"2024-09-20","current":-0.384297,"twenty":-2.220879,"median":-0.726938,"eighty":-0.391253,"marketCap":8932989},{"date":"2024-09-27","current":-0.420814,"twenty":-2.219166,"median":-0.713995,"eighty":-0.389826,"marketCap":9781825},{"date":"2024-10-04","current":-0.375603,"twenty":-2.219166,"median":-0.705506,"eighty":-0.388779,"marketCap":8730885},{"date":"2024-10-11","current":-0.484689,"twenty":-2.219166,"median":-0.691943,"eighty":-0.386036,"marketCap":11266594},{"date":"2024-10-18","current":-0.559329,"twenty":-2.219166,"median":-0.675446,"eighty":-0.386036,"marketCap":13001597},{"date":"2024-10-25","current":-0.336452,"twenty":-2.219166,"median":-0.638834,"eighty":-0.386036,"marketCap":7820838},{"date":"2024-10-31","current":-0.530552,"twenty":-2.18355,"median":-0.601504,"eighty":-0.386036,"marketCap":12332679},{"date":"2024-11-08","current":-0.740861,"twenty":-2.174646,"median":-0.630927,"eighty":-0.38823,"marketCap":17221309},{"date":"2024-11-15","current":-0.849939,"twenty":-2.111632,"median":-0.664773,"eighty":-0.389367,"marketCap":22332149},{"date":"2024-11-22","current":-1.580558,"twenty":-2.067561,"median":-0.675446,"eighty":-0.389764,"marketCap":41529165},{"date":"2024-11-29","current":-1.558504,"twenty":-1.993856,"median":-0.690544,"eighty":-0.390682,"marketCap":40949688},{"date":"2024-12-06","current":-1.477638,"twenty":-1.934558,"median":-0.69736,"eighty":-0.391557,"marketCap":38824940},{"date":"2024-12-13","current":-1.374718,"twenty":-1.867215,"median":-0.712804,"eighty":-0.392499,"marketCap":36120716},{"date":"2024-12-20","current":-1.065958,"twenty":-1.812401,"median":-0.717637,"eighty":-0.394326,"marketCap":28008041},{"date":"2024-12-27","current":-1.088012,"twenty":-1.791509,"median":-0.728386,"eighty":-0.395322,"marketCap":28587518},{"date":"2025-01-03","current":-0.867469,"twenty":-1.774231,"median":-0.730361,"eighty":-0.39568,"marketCap":22792751},{"date":"2025-01-10","current":-0.992443,"twenty":-1.764344,"median":-0.73424,"eighty":-0.39647,"marketCap":26076452},{"date":"2025-01-17","current":-0.658321,"twenty":-1.752027,"median":-0.729834,"eighty":-0.39647,"marketCap":17297380},{"date":"2025-01-24","current":-0.559444,"twenty":-1.742156,"median":-0.726938,"eighty":-0.39647,"marketCap":14699393},{"date":"2025-01-31","current":-0.459906,"twenty":-1.730007,"median":-0.713995,"eighty":-0.3984,"marketCap":12084021},{"date":"2025-02-07","current":-1.088012,"twenty":-1.727397,"median":-0.721011,"eighty":-0.399734,"marketCap":28587518},{"date":"2025-02-14","current":-0.992443,"twenty":-1.707609,"median":-0.729834,"eighty":-0.399947,"marketCap":26076452},{"date":"2025-02-21","current":-0.926281,"twenty":-1.702674,"median":-0.731091,"eighty":-0.399947,"marketCap":24338022},{"date":"2025-02-28","current":-0.612521,"twenty":-1.691156,"median":-0.729834,"eighty":-0.399947,"marketCap":16094000},{"date":"2025-03-07","current":-0.624578,"twenty":-1.650578,"median":-0.723974,"eighty":-0.400284,"marketCap":16410780},{"date":"2025-03-14","current":-0.571942,"twenty":-1.617436,"median":-0.713824,"eighty":-0.401215,"marketCap":15027763},{"date":"2025-03-21","current":-0.580763,"twenty":-1.605553,"median":-0.709155,"eighty":-0.402729,"marketCap":15259553},{"date":"2025-03-28","current":-0.511219,"twenty":-1.596023,"median":-0.693342,"eighty":-0.403425,"marketCap":13432270},{"date":"2025-04-04","current":-0.459715,"twenty":-1.584987,"median":-0.688902,"eighty":-0.403425,"marketCap":10179474},{"date":"2025-04-11","current":-0.669232,"twenty":-1.579798,"median":-0.693063,"eighty":-0.404476,"marketCap":14818796},{"date":"2025-04-17","current":-0.762727,"twenty":-1.576858,"median":-0.698757,"eighty":-0.405589,"marketCap":16889069},{"date":"2025-04-25","current":-0.815708,"twenty":-1.567326,"median":-0.703771,"eighty":-0.407877,"marketCap":18062224},{"date":"2025-05-02","current":-0.791432,"twenty":-1.558504,"median":-0.712804,"eighty":-0.410381,"marketCap":17524679},{"date":"2025-05-09","current":-0.680714,"twenty":-1.556948,"median":-0.713079,"eighty":-0.410531,"marketCap":15073040},{"date":"2025-05-16","current":-0.757287,"twenty":-1.55323,"median":-0.713725,"eighty":-0.411705,"marketCap":15073040},{"date":"2025-05-23","current":-0.755462,"twenty":-1.548212,"median":-0.715532,"eighty":-0.413178,"marketCap":15036720},{"date":"2025-05-30","current":-0.635937,"twenty":-1.533867,"median":-0.715532,"eighty":-0.413252,"marketCap":12657684},{"date":"2025-06-06","current":-0.601845,"twenty":-1.49389,"median":-0.713725,"eighty":-0.413637,"marketCap":11979114},{"date":"2025-06-13","current":-0.579566,"twenty":-1.491337,"median":-0.71226,"eighty":-0.415179,"marketCap":11535691},{"date":"2025-06-20","current":-0.49788,"twenty":-1.484989,"median":-0.706232,"eighty":-0.415179,"marketCap":9909811},{"date":"2025-06-27","current":-0.38649,"twenty":-1.477638,"median":-0.701377,"eighty":-0.415179,"marketCap":7692700},{"date":"2025-07-03","current":-0.414844,"twenty":-1.438928,"median":-0.693342,"eighty":-0.413227,"marketCap":8257056},{"date":"2025-07-11","current":-1.684355,"twenty":-1.438928,"median":-0.693202,"eighty":-0.413227,"marketCap":33525394},{"date":"2025-07-18","current":-1.123887,"twenty":-1.426793,"median":-0.701377,"eighty":-0.413252,"marketCap":22369845},{"date":"2025-07-25","current":-1.408554,"twenty":-1.420297,"median":-0.706232,"eighty":-0.414526,"marketCap":28035855},{"date":"2025-08-01","current":-1.087209,"twenty":-1.418827,"median":-0.712804,"eighty":-0.414844,"marketCap":21639801},{"date":"2025-08-08","current":-0.875894,"twenty":-1.410609,"median":-0.713774,"eighty":-0.415112,"marketCap":17433803},{"date":"2025-08-15","current":-0.869891,"twenty":-1.399128,"median":-0.7168,"eighty":-0.415179,"marketCap":17269086},{"date":"2025-08-22","current":-0.293416,"twenty":-1.396772,"median":-0.714044,"eighty":-0.415112,"marketCap":5824890},{"date":"2025-08-29","current":-0.333904,"twenty":-1.384858,"median":-0.713355,"eighty":-0.413227,"marketCap":6628654},{"date":"2025-09-05","current":-0.306566,"twenty":-1.377583,"median":-0.711715,"eighty":-0.410381,"marketCap":6085957},{"date":"2025-09-12","current":-0.318282,"twenty":-1.365896,"median":-0.706232,"eighty":-0.404476,"marketCap":6318541},{"date":"2025-09-19","current":-0.308519,"twenty":-1.353336,"median":-0.701377,"eighty":-0.401215,"marketCap":6124721},{"date":"2025-09-26","current":-0.294091,"twenty":-1.33881,"median":-0.693202,"eighty":-0.399947,"marketCap":5838288},{"date":"2025-10-03","current":-0.316401,"twenty":-1.31392,"median":-0.68726,"eighty":-0.39647,"marketCap":6281193},{"date":"2025-10-10","current":-0.322486,"twenty":-1.292622,"median":-0.675448,"eighty":-0.392499,"marketCap":6401985},{"date":"2025-10-17","current":-0.326542,"twenty":-1.284205,"median":-0.672663,"eighty":-0.38922,"marketCap":6482513},{"date":"2025-10-24","current":-0.308288,"twenty":-1.276188,"median":-0.670475,"eighty":-0.387098,"marketCap":6120137},{"date":"2025-10-31","current":-0.320457,"twenty":-1.271824,"median":-0.660381,"eighty":-0.385104,"marketCap":6361721},{"date":"2025-11-07","current":-0.336683,"twenty":-1.27075,"median":-0.656627,"eighty":-0.382558,"marketCap":6683833},{"date":"2025-11-14","current":-0.308288,"twenty":-1.248314,"median":-0.646559,"eighty":-0.37908,"marketCap":6120137},{"date":"2025-11-21","current":-0.506264,"twenty":-1.227901,"median":-0.642788,"eighty":-0.378051,"marketCap":10098454},{"date":"2025-11-28","current":-0.553956,"twenty":-1.216303,"median":-0.637388,"eighty":-0.378665,"marketCap":11049758},{"date":"2025-12-05","current":-0.564962,"twenty":-1.204728,"median":-0.625828,"eighty":-0.37908,"marketCap":11269290},{"date":"2025-12-12","current":-0.539282,"twenty":-1.202359,"median":-0.624725,"eighty":-0.379407,"marketCap":10757049},{"date":"2025-12-19","current":-0.480584,"twenty":-1.198139,"median":-0.617286,"eighty":-0.380537,"marketCap":9586214},{"date":"2025-12-26","current":-0.473247,"twenty":-1.193728,"median":-0.613551,"eighty":-0.381709,"marketCap":9439860},{"date":"2026-01-02","current":-0.429224,"twenty":-1.181411,"median":-0.606978,"eighty":-0.382558,"marketCap":8561733},{"date":"2026-01-09","current":-0.425556,"twenty":-1.152719,"median":-0.601338,"eighty":-0.382558,"marketCap":8488556},{"date":"2026-01-16","current":-0.381533,"twenty":-1.123887,"median":-0.596031,"eighty":-0.382558,"marketCap":7610429},{"date":"2026-01-23","current":-0.381533,"twenty":-1.113129,"median":-0.591212,"eighty":-0.381526,"marketCap":7610429},{"date":"2026-01-30","current":-0.385201,"twenty":-1.10426,"median":-0.583111,"eighty":-0.37908,"marketCap":7683607},{"date":"2026-02-06","current":-0.308931,"twenty":-1.10252,"median":-0.580763,"eighty":-0.3778,"marketCap":6162252},{"date":"2026-02-13","current":-0.278812,"twenty":-1.090904,"median":-0.575754,"eighty":-0.374195,"marketCap":5561467},{"date":"2026-02-20","current":-0.26843,"twenty":-1.088012,"median":-0.566497,"eighty":-0.373137,"marketCap":5354376},{"date":"2026-02-27","current":-0.310362,"twenty":-1.08753,"median":-0.56401,"eighty":-0.369399,"marketCap":6190791},{"date":"2026-03-06","current":-0.282371,"twenty":-1.0848,"median":-0.559387,"eighty":-0.36189,"marketCap":5632449},{"date":"2026-03-13","current":-0.174784,"twenty":-1.08267,"median":-0.557624,"eighty":-0.357961,"marketCap":3486416},{"date":"2026-03-20","current":-0.158448,"twenty":-1.081325,"median":-0.553956,"eighty":-0.344782,"marketCap":3160553},{"date":"2026-03-23","current":-0.149618,"twenty":-1.080993,"median":-0.553956,"eighty":-0.340848,"marketCap":2984440}],"updateTime":1774404344392},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CLDI\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2583124465","title":"Calidi Biotherapeutics reports third quarter net loss of $5.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583124465","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583124465?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:31","pubTimestamp":1763069510,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. reported a net loss of $5.2 million for the third quarter ended September 30, 2025, compared to a net loss of $5.1 million for the same period in 2024. A non-cash charge for deemed dividend on warrants increased the net loss attributable to shareholders to $10.8 million, while there was no such charge in the prior year period. Net loss per share, basic and diluted, was $2.21, down from $7.75 in the third quarter of 2024. Research and development expenses were $2.4 million, up from $2.2 million, and general and administrative expenses were $2.7 million, down from $3.1 million in the comparable period of 2024. The company had approximately $10.4 million in cash at the end of the quarter. Calidi raised $6.9 million in gross proceeds from an underwritten public offering, bringing total gross proceeds in 2025 to $23.0 million. Key business developments included new data presentations on CLD-401, further expansion of the RedTail platform, and the establishment of ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL42YSQJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2583351265","title":"Calidi Biotherapeutics Q3 EPS $(2.21) Misses $(1.68) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583351265","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583351265?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:22","pubTimestamp":1763068926,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(2.21) per share which missed the analyst consensus estimate of $(1.68) by 31.55 percent. This is a 71.67 percent increase over losses of $(7.80) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48851012/calidi-biotherapeutics-q3-eps-2-21-misses-1-68-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Calidi Biotherapeutics Q3 EPS $(2.21) Misses $(1.68) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2583749514","title":"Calidi Biotherapeutics Raises $6.9 Million and Advances RedTail Platform Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2583749514","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583749514?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:15","pubTimestamp":1763068533,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. announced its third quarter 2025 financial results and recent operational highlights. The company raised $6.9 million in gross proceeds through an underwritten public offering with new and existing investors, extending its financial runway and bringing the total gross proceeds raised in 2025 to $23.0 million. Calidi presented new data at the Society of Immunotherapy for Cancer  annual meeting demonstrating that its CLD-401 candidate can protect from immune clearance after systemic administration and effectively express genetic medicines at tumor sites. The company expanded the capabilities of its RedTail platform, including programmable membrane targeting and the addition of multiple payloads. Calidi also established a new Scientific Advisory Board to support the development of CLD-401 and further advance the RedTail platform.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provid","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL2zRcn0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210149790.SGD","BK4585","BK4588","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU0314104364.USD","LU2095319765.USD","CLDI","IE00B64PRP62.GBP","NDAQ","BK4139","IE00BKPKM429.USD","LU2210150020.SGD"],"gpt_icon":0},{"id":"2583514242","title":"Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2583514242","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583514242?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:15","pubTimestamp":1763068501,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA8KCKCW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2583277512","title":"Calidi Biotherapeutics Inc - Qtrly Net Loss per Share, Basic and Diluted, Was $2.21","url":"https://stock-news.laohu8.com/highlight/detail?id=2583277512","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583277512?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:15","pubTimestamp":1763068501,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA8KCKCW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2582718308","title":"Calidi Biotherapeutics Unveils Promising CLD-401 Data at SITC Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2582718308","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582718308?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:07","pubTimestamp":1762780034,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. announced new data on its lead therapeutic candidate, CLD-401, at the 2025 Society of Immunotherapy for Cancer  Annual Meeting. CLD-401, developed using Calidi's RedTail platform, is a tumor-tropic oncolytic virus designed for systemic administration that selectively replicates in tumor cells, induces immune priming at the tumor site, and expresses high levels of IL-15 superagonist in the tumor microenvironment. According to the company, preclinical syngeneic models demonstrated targeted delivery and expression of IL-15 superagonist in tumors with minimal systemic exposure. The latest results were presented at SITC 2025. Calidi is currently conducting IND-enabling studies for CLD-401 and anticipates submitting an Investigational New Drug  application by the end of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conte","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL6zwfQb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2095319765.USD","LU2210149790.SGD","LU2210150020.SGD","IE00BKPKM429.USD","LU0314104364.USD","BK4585","CLDI","BK4588","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","BK4112"],"gpt_icon":0},{"id":"2580731748","title":"Calidi Biotherapeutics to Present RedTail Platform at SITC Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2580731748","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580731748?lang=en_us&edition=fundamental","pubTime":"2025-11-04 21:00","pubTimestamp":1762261229,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. will hold an investor event at the Society of Immunotherapy for Cancer  Annual Meeting on Friday, November 7, 2025. The company will present updates on its RedTail platform and lead candidate, CLD-401.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 04, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL2JQKhb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210149790.SGD","BK4112","IE00B64PRP62.GBP","LU2095319765.USD","LU2210150020.SGD","BK4139","BK4588","NDAQ","CLDI","LU0314104364.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2580021363","title":"Calidi Biotherapeutics Selects Matica Bio for CLD-401 Oncolytic Virus Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2580021363","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580021363?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:01","pubTimestamp":1762174907,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. has entered into a strategic partnership with Matica Biotechnology, Inc. for the development and manufacturing of CLD-401, the first lead candidate from Calidi's RedTail platform. Under the agreement, Matica Bio will provide analytical development, process development, and GMP manufacturing services to support Calidi's IND submission for CLD-401, an oncolytic virus-based therapy designed for cancer treatment. This collaboration leverages Matica Bio's expertise in viral vector manufacturing to advance Calidi's clinical-stage immuno-oncology program.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire  on Nov","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL9XL7cH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2580416561","title":"Calidi Biotherapeutics Inc - Following Closing, Nova Cell Is No Longer Subsidiary of Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2580416561","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580416561?lang=en_us&edition=fundamental","pubTime":"2025-11-01 04:21","pubTimestamp":1761942088,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nFWN3WC1ON:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2580416308","title":"Calidi Biotherapeutics: on Oct 27, Enters Into Sra & Mpa, With Its Majority Owned Unit, Nova Cell","url":"https://stock-news.laohu8.com/highlight/detail?id=2580416308","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580416308?lang=en_us&edition=fundamental","pubTime":"2025-11-01 04:21","pubTimestamp":1761942088,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nFWN3WC1ON:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2580041637","title":"Calidi Biotherapeutics Inc - Sold and Transferred 22.5 Mln Shares of Nova Cell for $6 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2580041637","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580041637?lang=en_us&edition=fundamental","pubTime":"2025-11-01 04:21","pubTimestamp":1761942088,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nFWN3WC1ON:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2580141501","title":"Calidi Biotherapeutics Sells Majority Stake in Nova Cell for $6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2580141501","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580141501?lang=en_us&edition=fundamental","pubTime":"2025-11-01 04:16","pubTimestamp":1761941766,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. has completed an asset transaction with its majority-owned subsidiary, Nova Cell, Inc. Under a new Material Purchase Agreement, Calidi sold and transferred certain materials to Nova Cell, with Nova Cell also assuming specific defined liabilities and agreeing to usage restrictions. The agreement replaces a previous intellectual property assignment between the parties.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 31, 2025, and is solely responsible for the information contained ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL1k34LB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2579457011","title":"Calidi Biotherapeutics Unveils New Data on CLD-401 Tumor Therapy at SITC 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2579457011","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579457011?lang=en_us&edition=fundamental","pubTime":"2025-10-30 20:00","pubTimestamp":1761825636,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. announced that new data on its lead therapeutic candidate, CLD-401, will be presented at the Society for Immunotherapy of Cancer  40th Anniversary Annual Meeting, scheduled for November 7-9, 2025, in National Harbor, MD. The presentation, titled \"In Situ Tumor Delivery of IL-15 Superagonist via RedTail Gene Therapy Achieves Durable Tumor Clearance,\" is set for November 7, 2025. CLD-401, developed using Calidi's RedTail platform, is a tumor-tropic oncolytic virus engineered to target metastatic tumor sites, induce immune priming, and deliver high levels of IL-15 superagonist in the tumor microenvironment to activate NK and T-cell responses. The company is currently conducting IND-enabling studies for CLD-401 and anticipates submitting an Investigational New Drug  application by the end of 2026. Results from the current studies have not yet been presented and will be disclosed at the upcoming SITC meeting.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDLb2FgZh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BK4588","IE00B3QW5Z07.USD","BK4112","CLDI","BK4139","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BKPKM429.USD","NDAQ","LU2095319765.USD"],"gpt_icon":0},{"id":"2577369024","title":"Press Release: Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2577369024","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577369024?lang=en_us&edition=fundamental","pubTime":"2025-10-22 20:00","pubTimestamp":1761134400,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Oct. 22, 2025  -- Calidi Biotherapeutics, Inc.  , a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, today announced the formation of its Scientific Advisory Board  comprised of leading industry and academic researchers in with deep expertise in drug development.The SAB will work with Calidi to further develop its RedTail platform and advance CLD-401 into the clinic. RedTail is Calidi's groundbreaking approach to genetic medicines that utilizes an enveloped form of vaccinia virus genetically engineered to overexpress CD55 and avoid immune clearance, allowing for systemic delivery and targeting of genetic medicine payload to sites of disease.CLD-401, the first lead from the RedTail platform, is designed to home to metastatic sites after systemic administration, replicate only in tumors cells, induce an immune priming event at the tumor site, and express high levels of IL-15 superagonist in the tumor microen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0985481810.HKD","LU0868494617.USD","LU1883839398.USD","LU0456855351.SGD","IE00B19Z3B42.SGD","BK4592","IE00B19Z3581.USD","IE00BBT3K403.USD","IE00BLSP4239.USD","IE00BLSP4452.SGD","LU0321505439.SGD","LU1066051498.USD","BK4588","R","LU1894683264.USD","LU0289739699.SGD","SGXZ57979304.SGD","SG9999002232.USD","SG9999001176.SGD","BK4232","BK4022","IE000M9KFDE8.USD","BK4007","SG9999011175.SGD","LU0122379950.USD","LU0321505868.SGD","BK4533","LU1023059063.AUD","BK4585","BK4599","LU0234572021.USD","SG9999003800.SGD","LU0306807586.USD","BK4534","BK4550","LU0306806265.USD","LU1057294990.SGD","LU1066053197.SGD","SG9999013999.USD","LU0058720904.USD","CLDI","BK4581","SG9999001176.USD","LU1894683348.USD","LU0170899867.USD","BK4568","LU0225284248.USD","IE0002270589.USD","BK4139"],"gpt_icon":1}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":34,"code":"91000000","status":"200"}]}}